West Concord, MA – February 20, 2020 – Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world’s first fully automated bionic pancreas system called the iLet® today announced that Martha G. Aronson and Sean D. Carney have been appointed to the Company’s Board of Directors effective immediately. We are all […]
The iLet is a pocket-sized, wearable investigational medical device that autonomnously controls blood sugar in people with diabetes and other conditions — it is the world’s first bionic pancreas system FDA’s Breakthrough Device Designation Program provides Beta Bionics with priority review among other benefits related to FDA interaction The iLet Bionic Pancreas System was granted […]
A pilot study performed by researchers at the Massachusetts General Hospital tested autonomous glycemic control using the bionic pancreas system in both insulin-only and bihormonal configurations While using the bionic pancreas, the study subjects experienced improved glycemic control and decreased diabetes-management burden The study suggests that autonomous glycemic control using the bionic pancreas is worthy […]
ConvaTec is a leading global manufacturer of widely popular infusion sets offering a variety of patient choice Beta Bionics is developer of the iLet Bionic Pancreas System and is committed to device interoperability and patient choice ConvaTec will manufacture infusions sets for delivery of both insulin and glucagon via the iLet Bionic Pancreas System Boston, […]
The round was co-led by new investors Perceptive Advisors and Soleus Capital New investor Farallon Capital also participated in the round, as did previous Series B investors RTW Investments, ArrowMark Partners and funds managed by Eventide Asset Management Funds will support final product development, regulatory submission and commercial launch of the iLet TM Bionic Pancreas […]
First home-use trial of the iLet Bionic Pancreas System using pre-filled cartridges of dasiglucagon compatible with iLet has been successfully completed The preliminary study results reveal superior blood glucose control during the study period that used the bihormonal configuration of the iLet with dasiglucagon compared to the period that used the insulin-only configuration iLet therapy […]
First home-use trial of the bihormonal iLet Bionic Pancreas System with dasiglucagon in a pre-filled, commercial-ready, pump cartridge has been initiated by a clinical team at Massachusetts General Hospital The iLet Bionic Pancreas System is a pocket-sized, wearable medical device that autonomously controls blood-sugar levels in people with diabetes Dasiglucagon is a potential first-in-class stable […]
New investors include ArrowMark, LifeSci Venture Partners, and strategic partner, Dexcom RTW made an additional Series B investment Strategic partner, Zealand Pharma completed $5 million Series B investment BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) — Beta Bionics, Inc. – a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the world’s first autonomous […]
Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grant provides up to $2 million in funding over the next 24 months under the Fast-Track mechanism (pending demonstration of successful achievement of Phase I milestones) Research activities directed toward the Beta Bionics insulin-only and bihormonal bionic pancreas technology. Boston, MA – […]
The round was led by Eventide Asset Management Other institutional investors in Series B include RTW Investments Corporate strategic partner and Series A investor, Novo Nordisk, has also participated in Series B Corporate strategic partner, Zealand Pharm, previously committed $5m to Series B in December 2017 Boston, MA – September 17, 2018 – Beta Bionics, Inc. […]
Safety Information – The iLet Bionic Pancreas System is indicated for use by people with type 1 diabetes 6 years of age and older. The iLet Bionic Pancreas requires prescription by a physician. Refer to the iLet Bionic Pancreas System User Guide at www.betabionics.com/resouces/user-guides, or for complete safety information including indications, contraindications, warnings, cautions, compatible devices, compatible drugs and instructions, refer to www.betabionics.com/resources/safety. DO NOT start to use the iLet Bionic Pancreas System without adequate training. Incorrect use may result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.
Medical Disclaimer – This website is for information only and is not a substitute for medical advice and/or services from a healthcare provider. All personal health care decisions and treatment should be discussed with a healthcare provider who is familiar with your individual needs.
Copyright © 2024 Beta Bionics | Privacy Policy | Safety | Terms of Use | Cookies | Patents | Code of Conduct